Kintegral Advisory LLC Decreases Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Kintegral Advisory LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW) by 4.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 68,776 shares of the medical research company’s stock after selling 3,204 shares during the quarter. Kintegral Advisory LLC’s holdings in Edwards Lifesciences were worth $5,091,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. FSA Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences during the fourth quarter valued at $30,000. Prospera Private Wealth LLC bought a new position in Edwards Lifesciences in the third quarter valued at about $32,000. Avior Wealth Management LLC boosted its position in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the last quarter. Finally, JFS Wealth Advisors LLC grew its stake in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 166 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 2.0 %

Shares of Edwards Lifesciences stock opened at $73.25 on Friday. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $72.85 and a 200-day moving average price of $69.94. The firm has a market cap of $43.20 billion, a price-to-earnings ratio of 10.51, a PEG ratio of 4.82 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 26,489 shares of company stock valued at $2,002,829. 1.29% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Citigroup increased their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Canaccord Genuity Group upped their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. raised their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.